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Objectives This study sought to assess the effect of short-term apolipoprotein (apo) A-IMilano administration on plaque size
and on suspected markers of plaque vulnerability.
Background Long-term lipid-lowering interventions can regress and stabilize atherosclerotic plaques. However, the majority of
recurrent events occur early after the first episode. Interventions able to acutely induce plaque regression and
stabilization are lacking. Regression of human coronary lesions after 5 weeks of treatment with apoA-IMilano ad-
ministration has been shown. However, there are no data regarding its effect on plaque vulnerability.
Methods Advanced aortic lesions were induced in New Zealand White rabbits (n 40). Plaque size was assessed by magnetic
resonance imaging (MRI) at the end of atherosclerosis induction. Animals were randomized to placebo or apoA-IMilano
phospholipids (ETC-216), 2 infusions 4 days apart. After the last dose, another MRI study was performed and aortas
were processed for cellular composition and gene protein expression of markers associated with plaque instability.
Results Pre-treatment MRI showed similar plaque size in both groups, whereas post-treatment MRI showed 6%
smaller plaques in apoA-IMilano–treated animals compared with placebo (p  0.026). The apoA-IMilano treat-
ment induced a 5% plaque regression (p  0.003 vs. pre-treatment), whereas the placebo showed no sig-
nificant effect. Plaque regression by apoA-IMilano was associated with a reduction in plaque macrophage den-
sity and a significant down-regulation in gene and protein expression of tissue factor, monocyte chemoattractant
protein-1, and cyclooxygenase-2, as well as marked decrease in gelatinolytic activity. Conversely,
cyclooxygenase-1 was significantly up-regulated.
Conclusions Acute plaque regression observed after short-term apoA-IMilano administration was associated with a significant
reduction in suspected makers of plaque vulnerability in an experimental model of atherosclerosis. (J Am Coll
Cardiol 2008;51:1104–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.071l
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oipid-lowering interventions have shown that atherosclero-
is is not necessarily a constant cumulative process, as it is
easible to stop or even regress it (1–3). Initial studies
howed that atherosclerosis progression can be halted by
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ccepted September 17, 2007.ow-density-lipoprotein cholesterol lowering (2). More re-
ent evidence has suggested that increasing high-density-
ipoprotein (HDL) cholesterol can further regress athero-
clerotic lesions (3) The latter observation, added to other
re-clinical (4,5) and clinical work (6), set up the basis
See page 1110
or the HDL-raising approaches in the treatment of ath-
rosclerotic disease.
Acute complications of atherothrombosis are mostly sec-
ndary to plaque disruption with superimposed thrombus
ormation. Several post-mortem studies have strongly sug-
g
s
r
p
l
t
w
t
a
p
t
c
e
a
d
t
p
c
t
i
t
s
r
s
a
t
l
m
M
S
i
e
a
f
i
a
(
(
w
a
r
c
L
n
t
i
o
a
b
q
b
a
c
t
w
i
t
s
e
p
a
m
m
t
(
e
W
a
a
m
(
r
S
m
m
n
v
p
c
a
i
R
C
2
c
l
(
E
e
s
t
g
6
p
r
M
p
a
1105JACC Vol. 51, No. 11, 2008 Ibanez et al.
March 18, 2008:1104–9 Plaque Regression and Stabilization by ApoA-IMilanoested the importance of plaque composition, rather than its
tenotic severity, in the clinical manifestations of atheroscle-
osis. An increased macrophage density combined with the
resence of high gelatinolytic activity is among the patho-
ogical features associated with plaque vulnerability. In addi-
ion, it is known that certain components are clearly associated
ith high-risk plaques, especially because on plaque rupture
he local environment is highly pro-coagulant.
Statins have been shown to reduce cardiovascular events
nd even to induce plaque stabilization (7), but these
laque-stabilizing effects were always seen after long-term
reatments. However, the majority of recurrent cardiovas-
ular events take place within the first weeks after the initial
pisode (8).
Apolipoprotein (apo) A-IMilano is a mutant form of
poA-I associated with low incidence of cardiovascular
isease. Recombinant-ApoA-IMilano (rApoA-IM) has been
ested in numerous pre-clinical studies showing a reduced
laque size and lower lipid and macrophage plaque content
ompared with control subjects (9,10). It has also been
ested in humans, showing a plaque reduction after 5 weekly
njections (6). What remains to be determined is whether
his rapid plaque shrinkage is associated with plaque
tabilization.
In this study we have aimed to study the effects of
ApoA-IM not only on plaque size but also on its compo-
ition and activity. In a model of advanced human-like
therosclerotic lesions, short-term rApoA-IM administra-
ion induced an acute and significant regression of the
esions. Plaque regression was associated with cellular and
olecular changes, suggesting a plaque stabilizing effect.
ethods
ee the Online Appendix for an expanded methods section.
The atherosclerotic plaques were induced in the abdom-
nal aortas of New Zealand White rabbits (n  40). At the
nd of the atherosclerosis induction, all animals underwent
pre-treatment magnetic resonance imaging (MRI) study
or plaque size quantification. Animals were then random-
zed to receive 2 intravenous injections (75 mg/kg), 4 days
part, of rApoA-IM phospholipids (ETC-216, n  22)
Pfizer, Groton, Connecticut) or equal volume of placebo
n  18). Four days after the last dose, a second MRI study
as performed. Subsequently, rabbits were euthanized and
ortas were processed for further analyses.
The study protocol was approved by an institutional
esearch committee, and animals received humane care in
ompliance with the Guide for the Care and Use of
aboratory Animals.
On MRI, sequential transverse images (3-mm thick-
ess) of the 5 cm of abdominal aorta immediately distal
o the celiac trunk were obtained. The initial and final
mages were matched for anatomical position as previ-
usly described (11). Cross-sectional areas of the lumen ond vessel wall were determined
y a validated semiautomatic
uantification method (12).
The mean values for each rab-
it were considered for statistical
nalysis. A secondary analysis in-
luded the effect of treatments in
he most diseased lesion, which
as defined as the largest plaque
n 3 consecutive segments on ini-
ial MRI study.
Histological sections were
tained with Masson trichrome-
lastin stain, rabbit alveolar macro-
hage (RAM)-11 (macrophages),
nd alpha-actin (vascular smooth
uscle cells). Tissue factor (TF),
onocyte chemoattractant pro-
ein (MCP)-1, cyclooxygenase
COX)-1, and COX-2 antigen
xpression were analyzed by
estern blot analysis. Polymer-
se chain reaction was used to
ssess messenger ribonucleic acid expression of the same
arkers. Gelatinase activity of matrix metalloproteinase
MMP)-2 was assessed in protein extracts from atheroscle-
otic plaques by zymography.
tatistical analysis. Continuous variables are expressed as
ean  standard deviation. Statistical comparisons of
eans were made by Student paired and unpaired t tests for
ormally distributed variables. For nonnormally distributed
ariables, Wilcoxon and Mann-Whitney U tests were ap-
lied appropriately. A value of p  0.05 (2-tailed) was
onsidered statistically significant. The investigators had full
ccess to the data and take responsibility for its integrity. All
nvestigators have read and agree to the article as written.
esults
irculating levels of rApoA-IM peaked 30 min after ETC-
16 infusion. Thereafter there was a slow reduction in
irculating rApoA-IM levels. The increase in rApoA-IM
evels was still significant up to 48 h post-administration
Online Appendix).
ffect of rApoA-IMilano on vessel wall. Results of the
ffect of the treatments on vessel wall measurements as-
essed by MRI are presented in Table 1. Before treatments,
here were no differences in plaque size between the 2
roups. Post-treatment MRI showed that plaque size was
.2% smaller in animals receiving rApoA-IM compared with
lacebo (p  0.026). The administration of rApoA-IM
esulted in a 5% plaque regression (p  0.003 vs. initial
RI), whereas a nonsignificant effect was observed in the
lacebo group. Figure 1 shows an example of plaque regression
fter rApoA-IM administration. A similar effect was observed
Abbreviations
and Acronyms
apo  apolipoprotein
CETP  cholesteryl ester
transfer protein
COX  cyclooxygenase
ETC-216  recombinant
apolipoprotein A-IMilano and
1-palmitoyl-2-oleoyl
phosphatidylcholine
complexes
HDL  high-density
lipoprotein
MCP  monocyte
chemoattractant protein
MMP  matrix
metalloproteinase
MRI  magnetic resonance
imaging
rApoA-IM  recombinant
apolipoprotein A-IMilano
TF  tissue factorn the most diseased lesion: a statistically significant 6%
r
s
o
t
p
P
T
l
5
r
1
m
r
M
t
M
t
e
r
r
a
e

p
o
upplem
ot sign
1106 Ibanez et al. JACC Vol. 51, No. 11, 2008
Plaque Regression and Stabilization by ApoA-IMilano March 18, 2008:1104–9egression was observed in the rApoA-IM group, and no
ignificant effect in placebo. Despite the significant changes
bserved in plaque size, there were no significant differences in
he luminal size when comparing the pre-treatment and
ost-treatment values in either group.
laque cellular composition and gelatinolytic activity.
here was a significantly reduced macrophage density in the
esions of the rApoA-IM group compared with placebo. A
3% reduction in RAM-11 cells was observed in the
ApoA-IM group compared with placebo (0.7  0.2% vs.
.5  0.5%, p  0.008). The smooth muscle cell-to-
acrophage ratio was 2.1-fold higher in the aortas of the
ApoA-IM–treated animals (p  0.05). On zymography,
MRI Measurements
Table 1 MRI Measurements
Pre-Rx MRI
Plaque size
Lumen size
Most diseased lesion
Post-Rx MRI
Plaque size
Lumen size
Most diseased lesion
Change between pre-Rx MRI and post-Rx MRI (%)
Plaque size
Lumen size
Most diseased lesion
Data are expressed as mean SD (mm2). Additional information in s
apo  apolipoprotien; MRI  magnetic resonance imaging; NS  n
Figure 1 Atherosclerotic Plaque Regression in an Animal Rece
Magnetic resonance images before (A) and after (B) treatment at the same level
ing the autotracing of luminal and total vessel area contours. (E and F) Magnificat
by 20.5% after 2 doses of apoA-I . apo  apolipoprotein.MilanoMP-2 activity was significantly lower in rApoA-IM–
reated animals compared with placebo (p 0.001) (Fig. 2).
olecular footprint of rApoA-IMilano administration. At
he gene level, rApoA-IM significantly down-regulated the
xpression of TF, MCP-1, and COX-2 in the atheroscle-
otic lesions (p  0.01, p  0.04, and p  0.03 vs. placebo,
espectively). Concordant observations were rendered at the
ntigen level. The rApoA-IM down-regulated the protein
xpression of these parameters (p  0.03, p  0.029, and p
0.02 vs. placebo, respectively) (Fig. 3).
Conversely, we found an up-regulation in the gene and
rotein expression of markers associated with normalization
f endothelial activity. We detected increased gene and
poA-IMilano Placebo p Value
9.8 1.8 9.7 1.9 NS
0.6 3.8 10.3 3.9 NS
2.9 5.8 33.5 4.8 NS
9.3 1.7* 9.9 2.3 0.026
0.1 3.7 9.8 3.8 NS
0.9 5.9* 34.3 4.9 0.013
5.1 7 2.1 17 0.01
4.7 11 4.8 6 NS
6.1 7 2.4 16 0.02
entary file. *p  0.01 versus pre-Rx MRI.
ificant; Rx  treatment.
Recombinant apoA-IMilano
abdominal aorta. (C and D) The same images as panels A and B but highlight-
panels A and B drawing the plaque area. Plaque size in this segment regressedrA
1
3
1
3


iving
of the
ion of
a
r
s
F
D
S
s
v
o
l
m
a
fi
c
e
t
P
h
d
s
a
p
o
m
1107JACC Vol. 51, No. 11, 2008 Ibanez et al.
March 18, 2008:1104–9 Plaque Regression and Stabilization by ApoA-IMilanontigen COX-1 expression levels in the aortic lesions of the
ApoA-IM group (p  0.05 vs. placebo for both compari-
ons). The COX-1 and -2 gene expression is shown in
igure 4.
Figure 2 Gelatinolytic Activity of Atherosclerotic
Lesions in Animals Receiving rApoA-IM
Zymography performed in atherosclerotic lesions shows a markedly reduced
gelatinase activity after rApoA-IMilano administration compared with placebo.
apo  apolipoprotein; rApoA-IM  recombinant apolipoprotein A-IMilano.
Figure 3 Protein Expression in Aortic Lesions by Western Blot
Recombinant apoA-IMilano administration resulted in a significant antigen down-
regulation of TF, MCP-1, and COX-2. Conversely, COX-1 was up-regulated in
recombinant apoA-IMilano animals compared with placebo. aA-IM  apolipopro-
tein A-IMilano; apo  apolipoprotein; COX  cyclooxygenase; MCP  monocyte
chemoattractant protein; Plac  placebo; TF  tissue factor.iiscussion
ee the Online Appendix for an expanded discussion
ection.
We report the acute and significant regression of ad-
anced atherosclerotic lesions by short-term administration
f rApoA-IM by MRI. Furthermore, the shrinkage of the
esions was combined with a profound change in the
olecular footprint of the atherosclerotic lesions, suggesting
change into a more stable phenotype. To date, this is the
rst study correlating the in vivo plaque regression with
hanges in markers of plaque instability (both at the gene
xpression level and at the protein level) after rApoA-IM
reatment.
laque size. The effects of apoA-IMilano on plaque size
ave been previously reported by other investigators using
ifferent models of atherosclerosis (6,9,10). We report
imilar observations on plaque size, but in a model of more
dvanced atherosclerotic lesions more similar to human
athology (5).
We found a significant plaque regression with no effect
n lumen size. The advent of novel noninvasive imaging
odalities, such as MRI, enables the study of the real
Figure 4 COX-1 and COX-2 Gene Expression in
Aortic Lesions by Polymerase Chain Reaction
Recombinant apoA-IMilano administration resulted in COX-1 gene up-regulation
and COX-2 gene down-regulation. Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was used as the housekeeping gene. bp  base pairs; other abbrevi-
ations as in Figure 3.mpact of different approaches on the actual plaque size. We
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Plaque Regression and Stabilization by ApoA-IMilano March 18, 2008:1104–9reviously described the use of MRI to monitor plaque
rogression and regression by inducing atherosclerotic le-
ions, as described in the present work, and a subsequent
ithdrawal of the lipid overfeeding (13).
laque stability. The thrombogenic potential of disrupted
therosclerotic plaques seems to be highly modulated by
heir TF content (14). The significant reduction of TF
xpression at the vascular levels observed in the animals
eceiving rApoA-IM strongly suggests a reduction in the
hrombogenic potential of the residual lesions in the case of
n eventual disruption.
The reduction in MCP-1 expression seen in our work
ight have critical implications because MCP-1 is impli-
ated in the genesis and perpetuation of the atherosclerotic
rocess (via progressive monocyte recruitment and inflam-
ation environment generation). Its reduction may stop the
icious cycle of atherosclerosis perpetuation. In addition,
CP-1 down-regulation has been associated with the
revention of in-stent restenosis (15). In this context, Kaul
t al. (16) reported an inhibitory effect on neointimal
ormation post-stenting by the administration of apoA-
Milano, something that could have been secondary to the
CP-1 down-regulation by rApoA-IM administration.
The results found in this work on COX expression
uggest a dual beneficial effect of rApoA-IM administration:
n one hand, anti-inflammatory (down-regulation of COX-
), and on the other hand, a normalization of endothelial
ysfunction (COX-1 overexpression).
Degradation of the matrix components by certain pro-
eases (MMP) is believed to be a major player in plaque
nstability. Atherosclerotic plaques with high MMP activity
re considered vulnerable. In the present work, rApoA-IM
dministration resulted in a dramatic reduction in plaque
elatinolytic activity, as evidenced by lower MMP-2 activ-
ty. It was previously reported that HDL infusion was
ssociated with lower MMP antigen levels in rabbit athero-
clerotic plaques (17). The present work extends this find-
ng, providing changes in MMP activity after treatment
ith rApoA-IM.
Currently there are several interventions that have been
hown to induce plaque stabilization; however, the time
eeded to achieve this was relatively long (months). It is
mportant to remember that the majority of recurrent events
ake place in the early phase after the first ischemic event
8). In this regard, statins have been tested early after an
cute coronary syndrome, showing a reduction in recurrent
vents in some studies (18). Our results in an animal model
f atherosclerosis suggest that an acute loading intravenous
egimen of rApoA-IM might induce a rapid regression and
tabilization of high-risk atherosclerotic plaques.
The recent failure of a cholesteryl ester transfer protein
CETP) inhibitor shed doubt on the impact of increasing
DL for the treatment of atherosclerosis (19). Despite the
act that both approaches (CETP inhibition and apoA-I
nfusion) might be considered HDL-raising therapies, theechanisms of action are different. The reconstituted lipid-oor HDL used in the current study (rApoA-IMilano/
hospholipids) is a highly active molecule in removing
holesterol from extrahepatic tissues, whereas the fate and
ctivity of the large, cholesterol-rich HDL particle gener-
ted by the CETP inhibition is not completely understood
20).
The present work does not address whether rApoA-IM is
ore effective than native apoA-I in regressing and stabi-
izing atherosclerotic lesions. Different lines of clinical
vidence suggest that not all apoA-I/HDL compounds are
qually efficient, even at equivalent doses (6,21). The stron-
est evidence came from Shah’s group (22), showing that
acrophage-specific expression of the apoA-IM gene was
ore effective than wild-type apoA-I in reducing athero-
clerosis and plaque inflammation despite comparable cir-
ulating levels of the transgene and lipid profile.
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APPENDIX
or the expanded versions of the Methods and Discussion sections as well
s supplemental tables, please see the online version of this article.
